eligibility_summary
Eligible patients: histologically confirmed invasive HPV-related oropharyngeal or cervical cancer, ECOG performance status 0–1, and adequate hepatic, renal, pulmonary, and hematologic function. Exclusions: HIV seropositivity, active hepatitis C (HCV), or hepatitis B (HBV) infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Lenti-HPV-07, a lentiviral vector-based therapeutic cancer vaccine (gene therapy immunotherapy, IM injection). Mechanism: the vector delivers genes encoding HPV early oncogenic antigens (notably E6/E7 from HPV16/18), leading local antigen expression by transduced antigen-presenting cells and MHC I/II presentation that primes and expands HPV-specific T-cell responses. Targeted cells/pathways: activation of CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, antigen processing/presentation pathways, TCR-mediated recognition, effector killing of HPV+ tumor cells expressing E6/E7 in cervical or oropharyngeal squamous cancers. The study tests 1–2 IM doses (recurrent/metastatic vs newly diagnosed) to assess safety, immunogenicity, and preliminary efficacy.